---
document_datetime: 2025-10-16 14:45:34
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/avonex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: avonex-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 3.5619306
conversion_datetime: 2025-12-29 23:52:25.326403
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Avonex

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency' s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessmenthistory'section.Forthe completeproductlifecycleprocedures,youmayneed to alsorefer toEPAR-Procedural steps taken and scientific information after authorisation (archive).

| Applicationnumber   | Scope                              | Opinion/ Notification 1 issued on   | Commission Decision IssuedÂ²/ amendedon   | Product Information affected3   | Summary   |
|---------------------|------------------------------------|-------------------------------------|------------------------------------------|---------------------------------|-----------|
| Variation type IA / | A.ADMINISTRATIVE CHANGES-A.4Change | 16/10/2025                          |                                          | Annex II                        |           |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000300515                  | in the name and/or addressof:a manufacturer (including where relevant quality control testing sites);or anASMF holder; or a supplier of the active substance, startingmaterial,reagentorintermediate usedinthemanufactureoftheactive substance (where specified in the technical dossier) where no Ph. Eur. Certificate of Suitability is part of the approved dossier; or a manufacturer of a novel excipient (where specified in the technical dossier) - Accepted              |            |     |
|------------------------------------|-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|-----|
| VariationtypeIB/ EMA/VR/0000263564 | B.I.a.1 Change in the manufacturer of a startingmaterial/reagent/intermediateused in themanufacturingprocessof the active substanceorchangeinthemanufacturer (includingwhererelevantqualitycontrol testingsites)oftheactivesubstance,where noPh.Eur.Certificate ofSuitability is part of the approved dossier-B.I.a.1.f Changes to quality control testing arrangements for the activesubstance-replacementor additionof a site where batch control/testing takes place -Accepted | 14/05/2025 | N/A |